Effects of the oral probiotic Familact on dyspnea management in COPD patients: A randomized controlled trial

IF 2.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart & Lung Pub Date : 2025-02-27 DOI:10.1016/j.hrtlng.2025.02.002

Mehdi Aghamohammadi , Samad Ghodrati , Nooshin Jalili , Roghayeh Jafari , Effat Rafiee , Koorosh Kamali , Mahsa Ghasemi , Javad Alizargar

{"title":"Effects of the oral probiotic Familact on dyspnea management in COPD patients: A randomized controlled trial","authors":"Mehdi Aghamohammadi , Samad Ghodrati , Nooshin Jalili , Roghayeh Jafari , Effat Rafiee , Koorosh Kamali , Mahsa Ghasemi , Javad Alizargar","doi":"10.1016/j.hrtlng.2025.02.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests that oral probiotics may enhance the immune response in respiratory diseases, offering potential benefits in managing Chronic Obstructive Pulmonary Disease (COPD).</div></div><div><h3>Objectives</h3><div>This trial aims to evaluate whether the addition of the oral probiotic Familact to standard therapies significantly enhances dyspnea management in COPD patients compared to standard treatment alone.</div></div><div><h3>Methods</h3><div>In this single-blind randomized clinical trial 60 COPD patients randomly allocated into the control and intervention groups (<em>n</em> = 30). Over three months, the control group received standard treatment, while the intervention group received standard treatment plus oral Familact. Spirometry was conducted twice, and dyspnea was assessed four times using the Borg Scale Ratings (BORG) and Modified Medical Research Council Dyspnea Scale Scores in COPD patients (MMRC) scales and were evaluated using repeated measurement analysis.</div></div><div><h3>Results</h3><div>No significant change was observed in FEV1 post-intervention, but MMRC and BORG scores showed a statistically significant improvement in the intervention group compared to the control group (<em>P</em> < 0.01). Repeated measures tests based on estimated marginal means revealed significant MMRC differences within groups over time, with inter-group differences notable only between the first and second measurements. BORG showed significant within- and between-group differences at all time points, confirmed by post hoc tests.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that Familact, as an oral probiotic can significantly alleviate dyspnea in COPD patients, as reflected in notable improvements in BORG and MMRC scores. These findings underscore the potential of probiotics as an adjunctive therapy for COPD, particularly in improving patient-reported outcomes related to respiratory difficulty.</div></div>","PeriodicalId":55064,"journal":{"name":"Heart & Lung","volume":"71 ","pages":"Pages 63-68"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart & Lung","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0147956325000299","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Emerging evidence suggests that oral probiotics may enhance the immune response in respiratory diseases, offering potential benefits in managing Chronic Obstructive Pulmonary Disease (COPD).

Objectives

This trial aims to evaluate whether the addition of the oral probiotic Familact to standard therapies significantly enhances dyspnea management in COPD patients compared to standard treatment alone.

Methods

In this single-blind randomized clinical trial 60 COPD patients randomly allocated into the control and intervention groups (n = 30). Over three months, the control group received standard treatment, while the intervention group received standard treatment plus oral Familact. Spirometry was conducted twice, and dyspnea was assessed four times using the Borg Scale Ratings (BORG) and Modified Medical Research Council Dyspnea Scale Scores in COPD patients (MMRC) scales and were evaluated using repeated measurement analysis.

Results

No significant change was observed in FEV1 post-intervention, but MMRC and BORG scores showed a statistically significant improvement in the intervention group compared to the control group (P < 0.01). Repeated measures tests based on estimated marginal means revealed significant MMRC differences within groups over time, with inter-group differences notable only between the first and second measurements. BORG showed significant within- and between-group differences at all time points, confirmed by post hoc tests.

Conclusion

This study demonstrates that Familact, as an oral probiotic can significantly alleviate dyspnea in COPD patients, as reflected in notable improvements in BORG and MMRC scores. These findings underscore the potential of probiotics as an adjunctive therapy for COPD, particularly in improving patient-reported outcomes related to respiratory difficulty.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Heart & Lung 医学-呼吸系统

CiteScore

4.60

自引率

3.60%

发文量

184

审稿时长

35 days

期刊介绍： Heart & Lung: The Journal of Cardiopulmonary and Acute Care, the official publication of The American Association of Heart Failure Nurses, presents original, peer-reviewed articles on techniques, advances, investigations, and observations related to the care of patients with acute and critical illness and patients with chronic cardiac or pulmonary disorders. The Journal''s acute care articles focus on the care of hospitalized patients, including those in the critical and acute care settings. Because most patients who are hospitalized in acute and critical care settings have chronic conditions, we are also interested in the chronically critically ill, the care of patients with chronic cardiopulmonary disorders, their rehabilitation, and disease prevention. The Journal''s heart failure articles focus on all aspects of the care of patients with this condition. Manuscripts that are relevant to populations across the human lifespan are welcome.